Zobrazeno 1 - 10
of 132
pro vyhledávání: ''
Autor:
Banumathi Tamilselvan, Zachary Jackson, Susan Pereira Ribeiro, Jill S. Barnholtz-Sloan, Jaroslaw P. Maciejewski, David N. Wald, Kalpana Gupta, Ashish Sharma, Xuan Xu, Rafick-Pierre Sekaly, Robert Schauner, Anne Roe, Samuel Li, Robert S. Balderas, Tae Hyun Hwang, Lindsay Stetson, Slim Fourati, Marcos de Lima, Thomas LaFramboise, Dheepa Balasubramanian, Yogen Saunthararajah, Tammy Stefan
Publikováno v:
Leukemia
The prognosis of most patients with AML is poor due to frequent disease relapse. The cause of relapse is thought to be from the persistence of leukemia initiating cells (LIC's) following treatment. Here we assessed RNA based changes in LICs from matc
Publikováno v:
Leukemia
Causes of death, in particular deaths due to infection, have not been widely studied in randomised trials in chronic lymphocytic leukaemia. With long-term follow-up (median 13 years) we examined the cause of death in 600/777 patients in the LRF CLL4
Autor:
Ying Huang, James L. Fisher, Erin M. Bertino, Samantha Jaglowski, Kami J. Maddocks, Seema A. Bhat, John C. Byrd, Amy S. Ruppert, David A. Bond, Michael R. Grever, Dwight H. Owen, Jennifer A. Woyach, Kerry A. Rogers
Publikováno v:
Leukemia
7511 Background: Patients (pts) with chronic lymphocytic leukemia (CLL) suffer morbidity and mortality from CLL and increased risk for second primary neoplasia (SPN). BTK inhibitors (BTKi) are highly effective for the treatment (tx) of CLL and are as
Autor:
Christoph Schliemann, Joachim R. Göthert, Martin Dugas, Carsten Müller-Tidow, Georg Lenz, Christoph Röllig, Petra Mundmann, Richard F. Schlenk, Richard Noppeney, Uwe Platzbecker, Martin Bornhäuser, Stefanie Göllner, Walter E. Haefeli, Mascha Binder, Lutz P. Müller, Martin Wermke, Hubert Serve, Kathrin I. Foerster, Birgit Besenbeck, Study Alliance Leukemia, Jürgen Burhenne, Maxi Wass, Caroline Pabst, Jan-Henrik Mikesch
Publikováno v:
Leukemia
All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypro
Autor:
Jennifer A. Woyach, Fabienne Lucas, Farrukh T. Awan, Tracy Wiczer, Matthew B. Sullivan, Kerry A. Rogers, Audrey M. Sigmund, Qiuhong Zhao, Polina Shindiapina, Zeinab El Boghdadly, Tomas Guerrero, John C. Byrd, Seema A. Bhat, Lauren B. Levine, Luay Mousa
Publikováno v:
Leukemia
Autor:
Pierre Fenaux, Ana Garrido, David Martínez-Cuadrón, Uwe Platzbecker, Gabriel Ghiaur, Olga Salamero, Javier de la Serna, Lionel Adès, Sabine Kayser, Norbert Vey, Richard F. Schlenk, Xavier Thomas, Eva Lengfelder, Pau Montesinos, Arnaud Pigneux, Ramy Rahmé, Agnès Guerci-Bresler, Miguel A. Sanz, Marta Sobas, Cristina Gil, Mar Tormo, Mark J. Levis, Emmanuel Raffoux
Publikováno v:
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Scientia
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73.4 years) treated either with
Autor:
Alice S. Mims, Jessica Kohlschmidt, Sophia E. Maharry, Jonathan E. Kolitz, Christopher J. Walker, Shelley Orwick, Eunice S. Wang, Bayard L. Powell, James S. Blachly, Ann-Kathrin Eisfeld, Richard Stone, John C. Byrd, Deedra Nicolet, Albert de la Chapelle, Krzysztof Mrózek, Andrew J. Carroll, Clara D. Bloomfield
Publikováno v:
Leukemia
Targeted mutation assessment of 81 genes in 1021 adults with de novo acute myeloid leukemia (AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 52 (5.1%) patients, including 36 (5.2%) younger and 16 (4.8%) older patients, which
Publikováno v:
Leukemia. 32:2295-2298
Autor:
Anne Marinier, Arnaud Bonnefoy, Caroline Pabst, Vincent-Philippe Lavallée, Josée Hébert, Guy Sauvageau, Sébastien Lemieux, Jana Krosl, Georges-Etienne Rivard, Miriam Marquis, Jalila Chagraoui, Tara MacRae
Publikováno v:
Leukemia. 32:1349-1357
Acute promyelocytic leukemia (APL) is a medical emergency because of associated lethal early bleeding, a condition preventable by prompt diagnosis and therapeutic intervention. The mechanisms underlying the hemostatic anomalies of APL are not complet
Autor:
Francesco Passamonti, Curtis A. Hanson, Paola Guglielmelli, Maria Chiara Finazzi, Alberto Bosi, Meera Yogarajah, Vittorio Rosti, Naseema Gangat, Rhett P. Ketterling, Alessandro Rambaldi, Kebede H. Begna, Mrinal M. Patnaik, Mythri Mudireddy, Valerio De Stefano, Alessandro M. Vannucchi, Animesh Pardanani, Ayalew Tefferi, Francesco Mannelli
Publikováno v:
Leukemia
A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy. Median survival was 3.6 months, with no improvement over the last 15 years. Multivariable analys